Novo Nordisk Shares Plunge to Multi-Year Low Amid Regulatory and Clinical Setbacks

Novo Nordisk’s stock has entered a dramatic downturn, shedding more than half its value since the start of the year and currently trading at its lowest point in four years. Panicked investors are exiting their positions following a series of negative developments, though a surprise fast-track application to the U.S. Food and Drug Administration offers a potential lifeline. The critical question for the market is whether the severe sell-off represents an overreaction or signals deeper troubles ahead for the pharmaceutical giant.

In a strategic countermove, Novo Nordisk’s management has submitted an urgent application to the FDA seeking approval for a new, higher-dose 7.2 mg version of its weight-loss injection, Read more...